



ADVANCING RESEARCH IN RENAL AUTOIMMUNITY

A COLLABORATIVE SYMPOSIUM FOR INDUSTRY AND ACADEMIA

THURSDAY, 23RD JANUARY 2020
THE HOWARD THEATRE, DOWNING COLLEGE



Cambridge Biomedical Research Centre



LEARNING OBJECTIVES

- Promote industry-academic interactions and collaborative working relationships in autoimmune renal disease
- Discuss known and potential pathogenic pathways and treatment targets
- Discuss approaches to streamlining research and funding by utilisation of pathways and targets that cross cut disease areas

RESOURCES

<http://www.emi-training.org/>

RCP ACCREDITATION: 129616

'Advancing Research in Renal Autoimmunity; A Collaborative Symposium for Industry and Academia' has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 6 category 1 (external) CPD credits). Full conditions of approval are listed in RCP [guidelines](#).

SPONSORS

SANOFI GENZYME 

Retrophin[®]

 VIFOR
PHARMA

THE RENAL
ASSOCIATION
founded 1950 

 **BRS**
British Renal Society
Multi-professional working

 **Kidney Research UK**
Funding research to save lives

SCHEDULE

SPEAKERS

8.45-9.15 **Registration and Refreshments**
Grace Howard Room, Howard Theatre

9.15-9.20 **Introduction**
Howard Theatre

Professor Liz Lightstone and Professor David Jayne

Session 1

9.20-10.05 **Overview of academic research in the UK**

Chaired by Professor Liz Lightstone and Professor Phil Kalra

Academic networks and cross cutting research

Professor Phil Kalra

Hurdles to progress

Professor David Jayne

Clinical trial networks

Dr Thomas Hiemstra

Facilitation of a team culture to accelerate research

Mr Michael Nation

10.05-10.20 **Questions and Answers**

Session 2

10.20-11.05 **An industry perspective**

Chaired by Professor Caroline Savage and Dr Rona Smith

Novartis compounds in early development

Professor Nick Webb (Novartis)

An industry perspective- AstraZeneca

Professor Iain MacPhee (AstraZeneca)

An Industry Perspective -GSK

Dr Shaun Flint (GSK)

11.05-11.20 **Questions and Answers**

11.20-11.50 **Break – Grace Howard Room**

Session 3

11.50-12.45 **Collaborative success stories**

Chaired by Professor Jon Barratt and Professor Alan Salama

Complement inhibition in ANCA vasculitis

Professor David Jayne

Sparsentan in IgA nephropathy

Professor Jon Barratt

Fostamatinib in IgA nephropathy

Professor Fred Tam

Belimumab/rituximab in ANCA vasculitis

Dr Rachel Jones

12.45-13.00 **Questions and Answers**

13.00-14.15 **Lunch – Grace Howard Room**

Session 4

14.15-15.45	Targeting pathogenic pathways	Chaired by Professor Terry Cook and Professor Matthew Pickering
B cells		Dr Onno Teng
Belimumab in renal transplantation		Professor Menna Clatworthy
T cells		Professor Alan Salama
Complement		Professor Neil Sheerin
Cytokines		Dr David Close
Intracellular signalling; TYK2 inhibition		Dr Thomas Lehman
15.45-16.00	Questions and Answers	

16.00-16.30 **Break** – Grace Howard Room

Session 5

16.30- 17.45	Biomarkers and response prediction	Chaired by Professor David Jayne and Dr Allyson Egan
Biomarkers & response prediction		Dr Eoin McKinney
Biobanks - big data sources		Professor Jon Barratt
Industry collaboration to identify novel targets		Professor Peter Rutherford
Cutting edge technology		Professor Menna Clatworthy
How to use RaDaR, the Rare Renal Disease Registry		Dr Daniel Gale
17.45-18.00	Questions and Answers	
18.00	Round up session and closing remarks summary	Professor David Jayne and Professor Liz Lightstone

From 18.00 **Networking and Drinks reception**
Grace Howard Room

19.30 **Formal Dinner**
The Hall

BIOGRAPHIES



Professor Jon Barratt

The Mayer Professor of Renal Medicine, Department of Respiratory Sciences, University of Leicester

Jon leads the Renal Research Group within the College of Life Sciences, University of Leicester. His research is focussed on a bench to bedside approach to improving our understanding of the pathogenesis of IgA nephropathy a common global cause of kidney failure. Jon is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network. He works closely with pharmaceutical companies interested in new treatments for IgA nephropathy, and is Chief Investigator for a number of international randomised controlled Phase 2 and 3 clinical trials in IgA nephropathy, and a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Work group.



Dr Joseph Cheriyan

Consultant Physician & Clinical Pharmacologist at Addenbrooke's Hospital, Associate Lecturer, University of Cambridge, Director of the Cardiovascular Trials Office, Vice Chair of the Cambridge Research Ethics Committee, EMI Training Lead

Joseph is an active clinical researcher with interests in cardiovascular medicine particularly vascular function and inflammation and is uniquely the only MHRA accredited Phase I/II clinical triallist on the Cambridge Biomedical Campus working on early phase experimental medicine studies since 2006. His post combines NHS research within a University Department, in close collaboration with GSK's only remaining in house Clinical Unit, where he is seconded as a Senior Clinical Pharmacologist.



Professor Menna Clatworthy

Professor of Translational Immunology, Honorary Consultant Nephrologist; Director of Clinical Studies, Pembroke College, Director, NIH-OxCam PhD Scholars Programme

Menna took up a University Lecturer post in Cambridge in 2012, established her own lab in 2013 and was awarded a Readership and tenure in 2017, followed by a Professorship in 2019. She is a clinician scientist and divides her time between clinical work as a nephrologist, managing kidney and kidney-pancreas transplant recipients, and research. Her lab is focused on understanding the regulation of antibody generation and effector function, novel methods of targeting humoral immunity in kidney transplantation and investigating how the kidney microenvironment shapes local immune responses. This work ranges from experimental medicine studies in patients, in collaboration with industry partners, through to basic immunology studies, using murine models. The lab has a strong emphasis on integrating the use of primary human tissues into all of their studies, ensuring translational relevance, including collaborations with colleagues at the Wellcome Sanger Institute utilising single cell technologies to understand tissue-resident immune cells.

Dr David Close Medical Director, AstraZeneca

Currently Medical Director at AstraZeneca for 3 years David obtained his PhD at Keele University in Rheumatology and Clinical Immunology in 1997. He was clinical science leader and clinical development team leader at Roche Pharmaceuticals for 13 years and joined MedImmune as clinical director in inflammation and autoimmunity in 2010.



Professor Terry Cook

Professor of Renal Pathology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London

Terry Cook FMedSci is Professor of Renal Pathology at Imperial College, London and Consultant Renal Pathologist at Hammersmith Hospital. He has a major interest in how histological features in human renal biopsies can be used to predict outcome and response to treatment. He has organised international collaborative studies to develop consensus classifications of lupus glomerulonephritis, IgA nephropathy and

diabetic nephropathy.

Terry has a particular interest in the role of complement in glomerular injury and over the last few years our work has drawn attention to a group of human diseases with defects in the control of complement activation – C3 glomerulopathies. Together with Professor Matthew Pickering, he has set up an international group to study the natural history of C3 glomerulopathy and the way in which morphological features in the biopsy relate to presentation and clinical outcome.



Dr Allyson Egan

Honorary University Lecturer at the University of Cambridge and Locum Consultant Nephrologist at Addenbrooke's Hospital

Allyson is a Consultant Nephrologist with specialist interest in Vasculitis and Lupus. Education Lead for the KRUK GN Clinical Study Group. Council member and Past-President, Nephrology Section, Royal Society of Medicine. Chair of Care pathway Working Group and board member of UKIVAS.



Dr Shaun Flint

Early Development Leader at GlaxoSmithKline and a physician with nephrology and vasculitis experience

Shaun Flint is an Early Development Leader at GlaxoSmithKline and physician with nephrology and vasculitis background. He has worked in early phase R&D within industry for the last 3 years, where his current role involves leading a cross-functional team developing a novel asset in Ph2. Prior to that, he completed a translational medicine PhD at Cambridge University and specialist training in renal medicine in Australia.



Dr Daniel Gale

University College London, Centre for Nephrology, Associate Professor /Honorary Consultant

Nephrology, Division of Medicine, Faculty of Medical Sciences

Daniel undertook medical training at Cambridge University and moved to London for postgraduate training in nephrology. He is now St Peter's Associate Professor and Head of the Centre for Genetics and Genomics of the University College London Department of Renal Medicine, where he runs a research group aiming to improve understanding of the causes and mechanisms of genetic kidney disease. He leads the renal genetics service for North/Central London at the Royal Free Hospital, which provides specialist care for families with hereditary kidney problems including complement disorders, polycystic kidney disease, Alport syndrome and other familial disorders.

Dr Gale described clinically and identified the molecular defects responsible for the genetic diseases HIF2 α erythrocytosis with pulmonary hypertension, which results from a defect in cellular oxygen sensing, and CFHR5 nephropathy, which results from a defect of complement regulation and is endemic in Cypriots. He spent a period as Expert-in-Residence for the Melbourne Genomics Health Alliance and leads the renal component of the 100,000 Genomes Project, a UK-wide initiative to sequence the whole genomes of large numbers of patients with rare diseases, interpret the data and embed genomic medicine into clinical practice. As chair of the UK Renal Association Rare Disease committee he directs the Rare Renal Disease Registry (RaDaR) that now includes over 25,000 patients with rare kidney disease who are interested in participating in research.



Dr Thomas Hiemstra

Honorary consultant nephrologist, Cambridge University Hospitals Trust & trials methodologist, Cambridge Clinical Trials Unit.

Thomas Hiemstra is an honorary consultant nephrologist at Addenbrooke's Hospital. He is a trials methodologist with the Cambridge Clinical Trials Unit, where his primary focus is on efficient trials design. He leads a portfolio of trials in nephrology and related disciplines and serves on several trials steering committees and data monitoring committees. He chairs the UK Kidney Research Consortium Renal Trials Network (UKRTN), is president elect of the International Clinical Trials Centre Network (ICN) and leads the International Society of Nephrology Trials Toolkit working group.



Professor David Jayne

Professor of Clinical Autoimmunity, University of Cambridge; Director of the Vasculitis and Lupus Service, Addenbrooke's Hospital

A graduate of Cambridge University, David undertook postgraduate training at several London hospitals and was a research fellow at Cambridge and Harvard Universities. He has a portfolio of interventional clinical trials, and studies on biomarkers, histopathology and the clinical epidemiology of ANCA vasculitis that have been co-ordinated from Cambridge over the last 25 years. He is president of the European Vasculitis Society (EUVAS) and the network has expanded to collaborate with centres in North America, Australia/New Zealand and Japan and is now conducting clinical trials in over 100 centres. The studies have optimized the use of current therapies and explored newer biologic agents. They have defined the current 'standard of care' in ANCA vasculitis and have informed systematic reviews and international consensus management guidelines. Single and multi-centre clinical trials have been performed in ANCA vasculitis, Behçet's syndrome and lupus nephritis including the evaluation of mycophenolate mofetil, alemtuzumab, infliximab, adalimumab, rituximab and deoxyspergualin. David is medical advisor to UK, US and EU regulatory bodies, patients groups and professional organisations and has published more than 300 peer-reviewed journal articles, book chapters and reviews.



Dr Rachel Jones


Consultant in Nephrology and Vasculitis at Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital

Rachel is a Consultant Nephrologist at Addenbrooke's Hospital Cambridge. She undertook her training initially in London, then Cambridge from 2002-2011. In 2011 she gained her CCT and undertook an academic secondment from the University of Cambridge to GlaxoSmithKline where she her work included trials in membranous nephropathy and renal transplantation. She moved into her current NHS role in 2013. Alongside her clinical work in the vasculitis and lupus service, she is chief investigator on the EMINENT funded experimental medicine trial 'COMBIVAS' and principle investigator on several other industry and academic vasculitis and lupus trials. She is currently co-chair of the UK Kidney Research Consortium (UKKRC) glomerulonephritis clinical study group (GN CSG) and Eastern Renal Speciality Clinical Research Network (CRN) lead.

Professor Phil Kalra

Honorary Professor, University of Manchester; Academic Vice President, UK Renal Association; Chair, NIHR Renal Disorders national group, National Institute for Health Research; Consultant Nephrologist, Salford Royal NHS Foundation Trust

Philip graduated from Cambridge University and is Professor of Nephrology in Salford and the University of Manchester, Consultant Nephrologist since 1995. He has major research focus on renovascular disease, cardiovascular disease in CKD, CKD progression and iron use in CKD, and he leads the research team in Salford. He was Academic Vice President of the UK Renal Association 2016-19, Chair of the UK Kidney Research Consortium during this time and was Chair of the NIHR CRN Renal Disorders group from 2010 until 2018. He has been involved in the development of several large UK clinical trials in nephrology and cardiology, including the ASTRAL, PIVOTAL and IRONMAN trials, and he has played a role in amalgamating Cardio-Renal education and research within the UK.



Dr Thomas Lehman

Global Medical Affairs Leader, Bristol-Myers Squibb

Tom Lehman, PharmD is a Global Medical Affairs Leader at Bristol-Myers Squibb (BMS) with responsibility for both early and late stage medical affairs activities in Systemic Lupus (SLE), Lupus Nephritis (LN), and Cutaneous Lupus (CLE). Previous to this role, and over the last 7 years at BMS, Tom has led or contributed to medical affairs activities in Rheumatology (abatacept) or Transplant Nephrology (belatacept) including primary research and publications in Psoriatic Arthritis and Rheumatoid Arthritis.

Tom received his PharmD from the Philadelphia College of Pharmacy – University of the Sciences and completed his fellowship at Rutgers University through a public-private between Rutgers and Bristol-Myers Squibb.



Professor Liz Lightstone

Professor of Renal Medicine for the Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, Trustee of Kidney Research UK, Chair of World Kidney Day Planning Group (2018)

Chair of the Glomerulonephritis, lupus nephritis and vasculitis clinical study group, Liz completed her undergraduate medical training at Cambridge University for preclinical studies (first class degree), followed by clinical studies at King's College Hospital, London. She was runner up to Gold Medallist in the University of London (UCL) final MBBS with honours in four subjects. She completed her clinical training at London teaching hospitals and renal training initially at Guy's Hospital as a senior house officer (SHO) and subsequently at Hammersmith Hospital as registrar and senior registrar. She undertook a PhD in immunology at the ICRF tumour immunology unit at UCL (PhD awarded 1993) funded by a Medical Research Council (MRC) Training Fellowship. This was followed by an MRC Clinician Scientist Fellowship in the department of immunology at Hammersmith Hospital. Professor Lightstone was appointed senior lecturer in renal medicine and honorary consultant physician in 1995. She was appointed reader in 2011 and professor of renal medicine in 2014.



Dr Eoin McKinney

Wellcome Trust Intermediate Clinical Research Fellow, Department of Medicine, University of Cambridge

Research interest

Eoin has been using a custom spotted oligo microarray platform to investigate gene expression signatures in autoimmune diseases, specifically ANCA-associated systemic vasculitis and SLE. The highly heterogeneous clinical phenotypes seen in these syndromes make classification and diagnosis problematic and potentially confound attempts to further investigate underlying pathogenesis.

He is using a cell separation step in RNA extraction from whole blood to derive labelled cDNA from 5 cell subsets (CD4,8,14,16 and 19) as well as unseparated PBMC. Samples are collected during active disease and subsequently after 3 and 12 months of therapy, during which time patients undergo close clinical monitoring. This allows correlation of derived expression signatures with extensive clinical data and mining for novel disease biomarkers with both diagnostic and prognostic value.



Professor Iain MacPhee

Medical Director, Early Clinical Development, Cardiovascular, Renal and Metabolism at AstraZeneca

Iain received basic science training initially in Glasgow (BSc in Immunology) followed by a DPhil in experimental immunology in the MRC Cellular Immunology Unit in Oxford. He completed clinical training in Oxford with specialist training in Renal Medicine and Transplantation in Glasgow and London.

Iain joined AstraZeneca in Cambridge in May 2019 having spent 19 years as a clinical academic nephrologist at St George's, University of London, where he retains Visiting Professor status there. Iain practised general nephrology with a particular focus on renal transplantation and will be continuing to undertake a small amount of clinical practice. Iain's academic research focused on clinical pharmacology, in particular pharmacogenetics, in immunosuppression for renal transplantation and in acute kidney injury. Work in acute kidney injury included approaches to measurement of dynamic changes in GFR. His current work is focussed on the development of Phase 1 and Phase 2 clinical trials of new therapies for chronic kidney disease. Iain is on the editorial boards of Transplantation and Therapeutic Drug Monitoring.

Mr Michael Nation

Development Director of Research Development, Kidney Research UK

With over 26 years of development experience in the charity sector, Michael's current role underpins a progressive and partnership approach to deliver impact. Michael's development experience covers the research spectrum including global impact collaborations such as the PIVOTAL trial; the formation of a standardised and networked approach to the utilisation of imaging (MRI) – UK Renal Imaging Network (UKRIN) and the development of the UK's 1st centralised biobank - National Unified Renal Translational Research Enterprise (NURTuRE): NURTuRE – CKD and NURTuRE - Nephrotic Syndrome (NS). Michael's role also involves the development and promotion of patient, carer and public involvement and engagement in research.



Professor Matthew Pickering

Professor of Rheumatology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London

Matthew is a Clinician Scientist studying the role of complement in disease. Presently, his group are studying the mechanisms of kidney injury in C3 glomerulopathy.

Professor Matthew Pickering is an established international expert on the complement system and its role in health and disease. His research program has been funded by the Wellcome Trust since 2003 and he is presently a Wellcome Trust senior fellow in clinical science. His clinical expertise includes systemic lupus erythematosus and complement deficiency states. He is a professor of rheumatology at Imperial College London, academic director of the Imperial Lupus Centre and head of specialty, rheumatology at Imperial College Healthcare NHS Trust. His research has achieved international recognition for elucidating the relationship between uncontrolled complement activation and renal disease. His research program has utilised genetic characterisation of families with complement-mediated renal disease, the in vitro studies of complement regulatory proteins and the generation of unique murine models of complement-mediated kidney disease. He is a board member of both the International Complement Society and the European Complement Network and a fellow of the Royal College of Physicians.



Professor Peter Rutherford

Global Medical Lead for Rare Renal Diseases, Vifor Pharma, Zurich

Peter Rutherford qualified in Medicine from Newcastle University, UK and then completed nephrology training in the UK and at the Yale School of Medicine, USA, obtaining a PhD in 1994. For 11 years he was Senior Lecturer in Nephrology, Consultant Physician at University of Wales College of Medicine and chaired the Guidelines Review Group at NICE. He moved to Pharma in 2007 initially as Medical Director for Europe, Middle East and Africa at Baxter Healthcare and then Vice President of Integrated Market Access, Quintiles. Since 2017 he is Global Medical Lead for Rare Renal Diseases at Vifor Pharma in Zurich and is involved in both early and later stage drug development projects in rare kidney disease.



Professor Caroline Savage

Professor of Nephrology and former Vice President and Head, Experimental Medicine Unit GSK.

As a clinician scientist, Caroline has leadership experience in Academia, the NHS and Industry. Whilst Professor of Nephrology at University of Birmingham, UK, Caroline led an academic renal research laboratory that focused on autoimmune renal disease. In 2009, a sabbatical with GlaxoSmithKline (GSK) at their R&D site in Stevenage, UK was an exhilarating experience that changed her career path, such that she transitioned to industry in 2010. As VP, and Head of the Experimental Medicine Unit within the Immuno-Inflammation Therapy Area Unit, Caroline led a diverse group of scientists and clinicians to progress an exciting early phase portfolio of biologics and small molecules for autoimmune and inflammatory diseases. During her time at GSK, Caroline kept a very externalised view of the scientific and clinical landscape. This was facilitated by, for example, being a board member of the PSMB Board at the Medical Research Council for several years, by activities as a Fellow of the Academy of Medical Sciences and by membership of AcademiaNet. Caroline was also a GSK Senior Fellow, enabling excellence in science, serving as a role model to inspire passion for science, and contributing innovatively to the scientificCommunity for the benefit of patients. In April 2018, following retirement from GSK, Caroline pursued a long-standing ambition to sail around parts of the UK, which has now been accomplished. She will continue academic activities with MRC and Academy of Medical Sciences, while also serving as a Trustee for Kidney Research UK. Kidney Research UK is the leading charity dedicated to research into kidney disease in the UK that aims to find better treatments, and ultimately cures for kidney diseases (www.kidneyresearchuk.org). This is important as 60,000 people die prematurely in the UK each year because of chronic kidney disease and 64,000 people are being treated for end-stage renal failure. Alongside this new activity, Caroline is considering non-exec director roles in biotech and pharma.



Professor Alan Salama

Professor of Nephrology, Institute of Immunity and Transplantation, UCL

Alan Salama is a consultant in nephrology, specialising in inflammatory kidney diseases, systemic vasculitides and transplantation.

He trained in Oxford and London, completing a PhD at the Royal Postgraduate Medical School and a postdoctoral period at Brigham and Women's Hospital, Harvard Medical School.

In addition to his clinical work, he supervises a laboratory investigating autoimmune kidney disease and immune dysfunction, attempting to find better ways of diagnosing and treating immune mediated renal conditions, such as systemic vasculitis and SLE. Inflammation in the kidney may arise from many different causes, but commonly is due to a form of autoimmune disease, in which the kidney becomes a target of damage.



Professor Neil Sheerin

Professor of Nephrology, Faculty of Medical Sciences, Newcastle University

After training in Nephrology at Guy's Hospital Neil was a senior lecturer in Nephrology at King's College London before taking up his current post at Newcastle University and the Freeman Hospital five years ago.

Neil's clinical and laboratory research focuses on the immune mechanisms of renal disease exploring this interaction between adaptive and innate immunity, in particular how this leads to fibrotic injury in native and transplanted kidneys. Neil has educational roles with Newcastle University including being Director of the Certificate in Transplantation and Senior Tutor for Intercalation.



Dr Rona Smith


Senior research associate, University of Cambridge; Honorary consultant in nephrology and vasculitis

Rona is an Expert Advisor and Senior Clinical Trials Fellow at the CCTU, and an Honorary Consultant in Nephrology and Vasculitis at Cambridge University Hospitals NHS Foundation Trust. She is also a Senior Research Associate in nephrology and experimental medicine and a Staff Fellow at Trinity Hall, University of Cambridge. Her research focuses on the development and delivery of definitive trials in nephrology and clinical autoimmunity, with a focus on ANCA associated vasculitis.



Professor Frederick W.K. Tam, MBBChir (Cantab), PhD, FRCP, FHEA, is the Ken and Mary Minton Chair of Renal Medicine and an honorary consultant nephrologist at Hammersmith Hospital, Imperial College London.

Fred has been investigating the importance of cytokines in pathogenesis of glomerulonephritis, diabetic nephropathy and renal allograft rejection. His research group has developed experimental therapies of glomerulonephritis using soluble cytokine receptor, receptor antagonist and monoclonal antibodies, recombinant regulatory cytokines and signal transduction inhibitors. He has also applied the experience from cytokine analysis and proteomics to development of non-invasive biomarkers for kidney diseases. Together with the Transplantation Translational Research Group, he is investigating the novel mechanisms of renal transplant rejection and developing novel anti-rejection therapy (supported by Kidney Research UK Making Every Kidney Count Programme Grant). He is also the Founding Lead of the UK Rare Disease Group for Retroperitoneal Fibrosis. He has been collaborating with the industry in the preclinical and early clinical development of anti-inflammatory therapies.



Dr. Y.K.O. (Onno) Teng

Nephrology clinician-scientist, Department of Internal Medicine of the Leiden University Medical Center (LUMC)

Onno, MD, PhD is a Nephrology clinician-scientist at the department of Internal Medicine of the Leiden University Medical Center (LUMC). He is head of the Nephrology outpatient clinic and coordinator of the Leiden outpatient clinic for Lupus, Vasculitis and Complement-mediated Systemic diseases (LuVaCs) which accommodates top-referral, multidisciplinary, tertiary care on a regional and national level. He also leads and coordinates a clinical, multidisciplinary pathway aimed at counselling and guiding a pregnancy wish of patients with systemic lupus erythematosus (SLE) or antiphospholipid syndrome. He conducts a translational research program in the area of autoimmune glomerulonephritis related to SLE and ANCA-associated vasculitis (AAV). Onno's work is supported by grants from the Dutch Kidney Foundation and the Netherlands Organisation for Scientific Research.



Professor Nick Webb

Translational Medicine Discovery Director, Renal and Transplantation at Novartis Institutes for BioMedical Research


Nick is a Translational Medicine Director at Novartis Institutes for Biomedical Research in Basel, Switzerland. He is responsible for early phase studies of a rapidly expanding portfolio of new compounds under development for the treatment of adult and childhood kidney disease. He was previously a Consultant Paediatric Nephrologist at the Royal Manchester Children's Hospital, Honorary Professor of Paediatric Nephrology at the University of Manchester and Director of the NIHR Manchester Clinical Research Facility. His research work focused on clinical trials of new medicinal products and therapeutic regimens for childhood kidney disease, including the NIHR-funded PREDNOS studies of childhood idiopathic nephrotic syndrome. He is a keen skier and runner with plans to run the Jungfrau marathon this autumn.



Professor Ian Wilkinson

Professor of Therapeutics, Director of Cambridge Clinical Trials' Unit, Director of the Office of Translational Research, University of Cambridge, Director of the Experimental Medicine Training Initiative

Ian has a long track record in clinical pharmacology and arterial haemodynamics. His research interest is in clinical/experimental studies designed to understand the mechanisms underlying arteriosclerosis and cardiovascular disease, and to understand the importance of novel biomarkers of arterial function in risk prediction. He directs the Cambridge Clinical Trials' Unit and is also a director of the Office of Translational Research in Cambridge and the Experimental Medicine Initiative. He has considerable experience of translational research, and in forming academic collaborations with Industry.



Sanofi is a sponsor of this event but did not contribute to the content or agenda

